- Home
- VKTX
as of 01-16-2026 3:52pm EST
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.8B | IPO Year: | 2015 |
| Target Price: | $87.07 | AVG Volume (30 days): | 3.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.92 - $43.15 | Next Earning Date: | 02-04-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered VKTX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Viking Therapeutics Inc. (VKTX)
Chief Operating Officer
Avg Cost/Share
$33.74
Shares
57,661
Total Value
$1,901,405.31
Owned After
421,290
Chief Financial Officer
Avg Cost/Share
$33.00
Shares
57,661
Total Value
$1,896,969.39
Owned After
189,891
President & CEO
Avg Cost/Share
$33.74
Shares
233,409
Total Value
$7,692,120.64
Owned After
2,600,246
Director
Avg Cost/Share
$35.11
Shares
16,000
Total Value
$561,694.40
Owned After
132,036
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$35.00
Shares
6,185
Total Value
$216,491.70
Owned After
421,290
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$35.00
Shares
6,185
Total Value
$216,480.57
Owned After
189,891
SEC Form 4
President & CEO
Avg Cost/Share
$35.01
Shares
38,989
Total Value
$1,364,923.01
Owned After
2,600,246
SEC Form 4
Director
Avg Cost/Share
$35.57
Shares
60,000
Total Value
$2,134,278.00
Owned After
30,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Mancini Marianna | VKTX | Chief Operating Officer | Jan 5, 2026 | Sell | $33.74 | 57,661 | $1,901,405.31 | 421,290 | |
| ZANTE GREG | VKTX | Chief Financial Officer | Jan 5, 2026 | Sell | $33.00 | 57,661 | $1,896,969.39 | 189,891 | |
| Lian Brian | VKTX | President & CEO | Jan 5, 2026 | Sell | $33.74 | 233,409 | $7,692,120.64 | 2,600,246 | |
| FOEHR MATTHEW W | VKTX | Director | Jan 2, 2026 | Sell | $35.11 | 16,000 | $561,694.40 | 132,036 | |
| Mancini Marianna | VKTX | Chief Operating Officer | Oct 28, 2025 | Sell | $35.00 | 6,185 | $216,491.70 | 421,290 | |
| ZANTE GREG | VKTX | Chief Financial Officer | Oct 28, 2025 | Sell | $35.00 | 6,185 | $216,480.57 | 189,891 | |
| Lian Brian | VKTX | President & CEO | Oct 28, 2025 | Sell | $35.01 | 38,989 | $1,364,923.01 | 2,600,246 | |
| Rowland Charles A Jr | VKTX | Director | Oct 27, 2025 | Sell | $35.57 | 60,000 | $2,134,278.00 | 30,000 |
Compare VKTX vs Leading Stocks
See how VKTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VKTX Viking Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.